．

cGMP compliance by governmental inspections.

．

Start-up of Wulin Plant for dedicated commercial production of Latanoprost.

．

Filing of process patents that are advantageous for synthesizing PGF2α compounds with major patent offices worldwide.

．

Filing of first US DMF of the company for Latanoprost.

．

First successful US FDA Inspection.

．

Acquisition of Youth plant to accommodate growing business and employees.

．

Relocating Headquarters and Quality Unit to Youth plant.

．

Acquisition and construction of ChungLi plant for production of intermediates and starting materials.

．

Complete construction of 3 plants, all located in Taoyuan, Taiwan, comprising of more than 6 independent production lines, dedicated for manufacturing of different prostaglandin APIs, and one intermediate building for producing intermediates in tons scale.

．

The company owns 3 active DMFs with US FDA and has developed filing experiences in Japan, Canada, China, Australia, New Zealand, and EU countries.　

．

4 patents for proprietary synthesis of Prostaglandin F2α-related compounds such as Latanoprost, Bimatoprost, and Travoprost have been granted approval in US.

．

Second successful US FDA Inspection for Latanoprost and Bimatoprost.

．

Acquisition of Yangmei plant for expansion of state-of-the-art production workshops.

．

Certified as a supplier of reference standards for US Pharmacopeia.

．

Successful inspection by COFEPRIS.

．

Third successful US FDA Inspection. Three more US DMFs and EU DMF are filed.

．

The patent of processes and intermediates for the preparations of isomer free prostaglandins has been granted approval in US.

．

Complete construction of Yangmei plant, capable of providing 10 more dedicated and independent production workshops for increasing market demands.

．

Successful inspection by PMDA.

．

Filed more DMFs in US, EU, Canada, Japan...etc.